{
  "id": "5a7d5580faa1ab7d2e00001a",
  "type": "list",
  "question": "What in vivo tau tracers are being used?",
  "ideal_answer": "in-vivo tau PET imaging ligands include [(18)F]THK523, [(18)F]THK5117, [(18)F]THK5105 and [(18)F]THK5351, [(18)F]AV1451(T807) [(11)C]PBB3, (18)F-THK5117, [(18)F]T808, 18F-RO6958948.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26572762",
    "http://www.ncbi.nlm.nih.gov/pubmed/27334944"
  ],
  "snippets": [
    {
      "text": "The recent development of selective in-vivo tau PET imaging ligands including [(18)F]THK523, [(18)F]THK5117, [(18)F]THK5105 and [(18)F]THK5351, [(18)F]AV1451(T807) and [(11)C]PBB3 has provided information about the role of tau in the early phases of neurodegenerative diseases, and provided support for diagnosis, prognosis, and imaging biomarkers to track disease progression.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26572762",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tau positron emission tomography radiolabelled probes such as T807, THK-5117, and PBB3 can image the pathology of the disease in vivo. The 18F-labeled tau imaging agents 18F-THK-5351, 18F-T807 (18F-AV-1451), and 18F-RO6958948 are presently under evaluation in clinical studies and clinical trials worldwide. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27334944",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "[(11)C]PBB3, [(18)F]AV1451, T807, [(18)F]T808, [(18)F]THK523, [(18)F]THK5105, [(18)F]THK5117, [(18)F]THK5351, 18F-RO6958948"
}